The contributions of the tissue inhibitor of metalloproteinase-1 genotypes to triple negative breast cancer risk
Tóm tắt
The tissue inhibitors of metalloproteinases (TIMPs) are a family of multifunctional proteins which have been shown to be upregulated in various types of cancers. However, the contribution of TIMPs in breast cancer is not fully understood, not to mention triple negative breast cancer (TNBC). This study’s aim was to evaluate the contribution of TIMP-1 rs4898, rs6609533, and rs2070584 genotypes to the risk of breast cancer, especially the subtype of TNBC. The contributions of these TIMP-1 genotypes to cancer risk were examined among 1232 breast cancer patients and 1232 healthy controls, and several clinicopathologic factors were also analyzed. The results showed that the percentages of CC, CT, and TT of TIMP-1 rs4898 were differentially distributed at 28.5%, 33.1% and 38.4% in the breast cancer patient group and 34.5%, 41.0% and 24.5% in the control group, respectively (P for trend = 7.99*10-13). It was also found that the CC genotype carriers were of increased risk for breast cancer (odds ratio = 1.90, 95% confidence interval = 1.55-2.33, P = 0.0001) than the TT genotype carriers. In addition, we analyzed the allelic frequency distributions of all three TIMP-1s, and the results showed that the C allele of TIMP-1 rs4898 contributes to an increase in breast cancer susceptibility (P = 2.41*10-12). On the other hand, there was no difference found in the distribution of genotypic or allelic frequencies among the patients and the controls for TIMP-1 rs6609533 and rs2070584. Thus, it is our conclusion that the CC genotype of TIMP-1 rs4898 compared to the TT wild-type genotype may increase the risk for breast cancer, especially TNBC in Taiwan, and may serve as an early detective and predictive marker.
Tài liệu tham khảo
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5–29.
Cheng SH, Tsou MH, Liu MC, Jian JJ, Cheng JC, Leu SY, et al. Unique features of breast cancer in Taiwan. Breast Cancer Res Treat 2000; 63: 213–23.
Kuo WH, Yen AM, Lee PH, Chen KM, Wang J, Chang KJ, et al. Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women. Br J Cancer 2009; 100: 563–70.
Murphy G, Docherty AJ. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 1992; 7: 120–5.
Woessner JF, Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. Faseb J 1991; 5: 2145–54.
Delacourt C, Le Bourgeois M, D’Ortho MP, Doit C, Scheinmann P, Navarro J, et al. Imbalance between 95 kDa type IV collagenase and tissue inhibitor of metalloproteinases in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med 1995; 152: 765–74.
Ben Nejima D, Ben Zarkouna Y, Gammoudi A, Manai M, Boussen H. Prognostic impact of polymorphism of matrix metalloproteinase-2 and metalloproteinase tissue inhibitor-2 promoters in breast cancer in Tunisia: case-control study. Tumour Biol 2015; 36: 3815–22.
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 18–43.
Su CH, Chang WS, Hu PS, Hsiao CL, Ji HX, Liao CH, et al. Contribution of DNA Double-strand Break Repair Gene XRCC3 Genotypes to Triple-negative Breast Cancer Risk. Cancer Genomics Proteomics 2015; 12: 359–67.
Su CH, Hsiao CL, Chang WS, Liu LC, Wang HC, Tsai CW, et al. Evaluation of the contribution of cyclooxygenase 2 genotypes to breast cancer in Taiwan. Anticancer Res 2014; 34: 6711–6.
Nagase H, Woessner JF, Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491–4.
Surlin V, Ioana M, Plesea IE. Genetic patterns of metalloproteinases and their tissular inhibitors - clinicopathologic and prognostic significance in colorectal cancer. Rom J Morphol Embryol 2011; 52: 231–6.
Liu D, Guo H, Li Y, Xu X, Yang K, Bai Y. Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis. PLoS One 2012; 7: e31251.
Chiu CF, Wang HC, Wang CH, Wang CL, Lin CC, Shen CY, et al. A new single nucleotide polymorphism in XRCC4 gene is associated with breast cancer susceptibility in Taiwanese patients. Anticancer Res 2008; 28: 267–70.
Wang HC, Chiu CF, Tsai RY, Kuo YS, Chen HS, Wang RF, et al. Association of genetic polymorphisms of EXO1 gene with risk of breast cancer in Taiwan. Anticancer Res 2009; 29: 3897–901.
Wang HC, Liu CS, Chiu CF, Chiang SY, Wang CH, Wang RF, et al. Significant association of DNA repair gene Ku80 genotypes with breast cancer susceptibility in Taiwan. Anticancer Res 2009; 29: 5251–4.
Wang H, Brown J, Martin M. Glycogen synthase kinase 3: a point of convergence for the host inflammatory response. Cytokine 2010; 53: 130–40.
Wang HC, Chang WS, Tsai RY, Tsai CW, Liu LC, Su CH, et al. Association between ataxia telangiectasia mutated gene polymorphisms and breast cancer in Taiwanese females. Anticancer Res 2010; 30: 5217–21.
Liu LC, Su CH, Wang HC, Tsai CW, Chang WS, Ho CY, et al. Significant association of caveolin-1 (CAV1) genotypes with breast cancer in Taiwan. Anticancer Res 2011; 31: 3511–5.
Su CH, Liu LC, Hsieh YH, Wang HC, Tsai CW, Chang WS, et al. Association of Alpha B-Crystallin (CRYAB) genotypes with breast cancer susceptibility in Taiwan. Cancer Genomics Proteomics 2011; 8: 251–4.
Huang CY, Chang WS, Shui HA, Hsieh YH, Loh CH, Wang HC, et al. Evaluation of the contribution of methylenetetrahydrofolate reductase genotypes to Taiwan breast cancer. Anticancer Res 2014; 34: 4109–15.
Liu LC, Su CH, Wang HC, Chang WS, Tsai CW, Maa MC, et al. Contribution of personalized Cyclin D1 genotype to triple negative breast cancer risk. Biomedicine (Taipei) 2014; 4: 3.